Developing new vaccines to treat opioid use disorder
Nanotechnology-based platform for the development of next-generation vaccines against opioid use disorder (OUD)
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF MINNESOTA · NIH-10917103
This study is exploring new vaccines to help people with opioid use disorder by reducing the risk of overdose, offering a promising alternative to current treatments that may not work well for everyone.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-10917103 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative vaccines to combat opioid use disorder (OUD) and reduce the risk of overdose. By utilizing a novel nanoparticle-based platform, the project aims to enhance the effectiveness of these vaccines, which could provide a long-lasting treatment option. The approach involves understanding the molecular and cellular mechanisms that contribute to the vaccines' efficacy, with the goal of improving patient outcomes. Patients may benefit from a new alternative to current therapies that often have limited effectiveness and potential for abuse.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking alternative treatment options.
Not a fit: Patients who are not struggling with opioid use disorder or those who have not been diagnosed with substance use disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals struggling with opioid use disorder.
How similar studies have performed: Previous clinical trials of addiction vaccines have shown proof of efficacy, indicating that this approach has potential based on earlier successes.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAMID, FATIMA ALAMIN AWAD ALKAREEM — UNIVERSITY OF MINNESOTA
- Study coordinator: HAMID, FATIMA ALAMIN AWAD ALKAREEM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.